Abstract 785P
Background
GTN involves malignant entities, such as choriocarcinoma (GCC), epithelioid trophoblastic tumor (ETT), and placental site trophoblastic tumor (PSTT), all of which can metastasize and be fatal if not treated in a timely and effective manner. We aimed to develop machine-learning (ML)-based prognostic models for patients with GTN to improve treatment decisions and personalized medicine.
Methods
The SEER database provided the data used for this study’s analysis (2000–2019). Patients were excluded if they did not meet certain criteria, such as a histology-confirmed diagnosis, previous history of cancer or other concurrent malignancies, non-placental origins, or unknown data. Cox regression and ML algorithms were used to construct prognostic models for predicting the 5-year survival. Patient records were randomly divided into a training set (70%) and a validation set (30%). A validation method incorporating the area under the curve (AUC) of the receiver operating characteristic curve was used to validate the accuracy and reliability of ML models.
Results
This study included 725 patients, of whom 139 had ETT, 107 had PSTT, and 479 had GCC. The median age was 37 years, and the most common stage was distant metastasis (n=330). The average tumor size was 6.13 cm, and 75.9% of patients underwent chemotherapy, 57.9% underwent surgery, and 4.3% underwent radiotherapy. Multivariate Cox regression revealed that older age, marital status, metastasis, and radiotherapy were poor prognostic factors, whereas surgery was a good prognostic factor. ML models revealed that the most important factors that influenced the model prediction performance were tumor size, years of diagnosis, and race. The online calculator, which is based on ML models, allows for real-time personalized survival predictions, and can be accessed through the following link: https://sakhrshwayyat.shinyapps.io/Gestational_Trophoblastic_Neoplasia/.
Conclusions
Our study revealed the critical components of clinical decision-making. The designed models and online prediction resources can significantly facilitate personalized treatment planning and enhance the clinical outcomes of patients with GTN.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
900P - Notch inhibitor AL101 prior to surgery in patients (pts) with Notch1 activated adenoid cystic carcinoma (ACC): Safety and efficacy in a window of opportunity study
Presenter: Renata Ferrarotto
Session: Poster session 02
901P - A phase II trial of neoadjuvant nivolumab, docetaxel, and cisplatin therapy followed by surgery and radiation therapy for resectable high-grade salivary gland carcinoma
Presenter: Sehhoon Park
Session: Poster session 02
902P - Comparison of progression free and overall survival (OS) with bicalutamide and 4-weekly or 12-weekly triptorelin in androgen receptor positive (AR+) salivary gland cancer (SGC)
Presenter: Amelia Handley
Session: Poster session 02
903P - Patterns and predictors of recurrence-free survival (RFS) in salivary gland cancers (SGCs): A Spanish multicenter study
Presenter: Alexandre Izquierdo Miranda
Session: Poster session 02
904P - Analysis of TP63 immunohistochemistry scores (IHC) by primary site and between primary and metastatic tumours in adenoid cystic carcinoma (ACC)
Presenter: Laura Spurgeon
Session: Poster session 02
905P - Validation of MYC/TP63 classification for adenocystic carcinomas of salivary glands
Presenter: Panagiota Economopoulou
Session: Poster session 02
906P - Prognostic impact and therapeutic implications of comprehensive genomic profiling (CGP) in non-metastatic salivary gland cancers (nmSGC)
Presenter: Mario Balsa Pena
Session: Poster session 02